Trinity Biotech PLC (TRIB) shareholders
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 30, 2026Score 1/30
$6.01+0.63 (+11.81%)
Close on Nov 17, 2026Market cap $112.45MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 374M shares
Institutional holders
20
2 new, 4 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Joseph Edelman Joint filing with Perceptive Advisors LLC (9.90%), Perceptive Credit Advisors LLC (9.90%) and 2 more | 3,424,019,957 | 9.90% | 13D (active) amendment | Apr 30, 2026 |
| Perceptive Credit Advisors LLC Joint filing with Perceptive Advisors LLC (19.80%), Joseph Edelman (19.80%) and 2 more | 85,800,000 | 19.80% | 13D (active) amendment | Mar 21, 2025 |
| DAYLI Partners, Inc. Joint filing with MiCo IVD Holdings, LLC (18.00%), DAYLI TRINITY HOLDINGS, Ltd. (18.00%) and 1 more | 69,450,720 | 18.00% | 13D (active) amendment | Dec 17, 2024 |
| MiCo IVD Holdings, LLC Joint filing with AI n M net Ltd. (17.00%), Joon Ho Lee (17.00%) | 69,450,720 | 17.00% | 13D (active) amendment | Dec 8, 2025 |
| Perceptive Advisors LLC Joint filing with Perceptive Credit Advisors LLC (9.99%), Joseph Edelman (9.99%) and 2 more | 54,148,590 | 9.99% | 13D (active) amendment | Nov 6, 2026 |
| Novus Diagnostics Ltd. | 1,119,988 | 5.99% | 13G (passive) | Dec 23, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TRIB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hunter Associates Investment Management LLC | 22,040 | 0.01% | $251.00K | +4,166 | 0.03% |
| Williams & Novak, LLC | 4,685 | 0.00% | $54.64K | +1,097 | 0.04% |
| Cambridge Investment Research Advisors, Inc. | 1,486 | 0.00% | $18.00K | +743 | 0.00% |
| Susquehanna International Group, Llp | 895 | 0.00% | $10.44K | New | 0.00% |
| Moss Adams Wealth Advisors LLC | 856 | 0.00% | $9.98K | – | 0.00% |
| Inspirion Wealth Advisors, LLC | 833 | 0.00% | $8.92K | – | 0.00% |
| Raymond James Financial Inc | 677 | 0.00% | $7.90K | – | 0.00% |
| Becker Capital Management Inc | 600 | 0.00% | $7.00K | – | 0.00% |
| LPL Financial LLC | 589 | 0.00% | $6.87K | +88 | 0.00% |
| Geode Capital Management, LLC | 420 | 0.00% | $4.90K | −135 | 0.00% |
| Rhumbline Advisers | 312 | 0.00% | $3.64K | +127 | 0.00% |
| Jones Financial Companies Lllp | 121 | 0.00% | $1.32K | −6 | 0.00% |
| Osaic Holdings, Inc. | 117 | 0.00% | $1.37K | New | 0.00% |
| Wells Fargo & Company/Mn | 83 | 0.00% | $972 | – | 0.00% |
| Farther Finance Advisors, LLC | 67 | 0.00% | $778 | – | 0.00% |
| UBS Group AG | 37 | 0.00% | $431 | +3 | 0.00% |
| Morgan Stanley | 13 | 0.00% | $156 | – | 0.00% |
| Simplex Trading, LLC | 12 | 0.00% | $137 | −7 | 0.00% |
| Atwood & Palmer Inc | 1 | 0.00% | $8 | – | 0.00% |
| CoreCap Advisors, LLC | 0 | 0.00% | $0 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 20 | 0M | 0.0% | 2 / 6 | 3 / 4 | 0M | 0M |
| Q1 2026 | 23 | 0M | 0.0% | 5 / 4 | 3 / 8 | 0M | 0M |
| Q4 2025 | 27 | 0M | 0.0% | 6 / 9 | 3 / 7 | 0M | 0M |
| Q3 2025 | 28 | 0M | 0.0% | 7 / 4 | 4 / 4 | 0M | 0M |
| Q2 2025 | 25 | 0M | 0.0% | 3 / 4 | 3 / 5 | 0M | 0M |
| Q1 2025 | 27 | 0M | 0.0% | 8 / 0 | 8 / 4 | 0M | 0M |
| Q4 2024 | 23 | 0M | 0.0% | 9 / 1 | 3 / 5 | 0M | 0M |
| Q3 2024 | 19 | 0M | 0.0% | 2 / 4 | 2 / 3 | 0M | 0M |
| Q2 2024 | 20 | 0M | 0.0% | 6 / 1 | 3 / 5 | 0M | 0M |
| Q1 2024 | 19 | 0M | 0.0% | 6 / 2 | 4 / 12 | 0M | 0M |
| Q4 2023 | 26 | 0M | 0.0% | 7 / 1 | 6 / 1 | 0M | 0M |
| Q3 2023 | 20 | 0M | 0.0% | 1 / 1 | 4 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Murphy | Interim CFO | – | – | Apr 3, 2026 |
| Ronan O'Caoimh | Director | 486,208 | 0.13% | Apr 8, 2026 |
| John Gillard | Director | 10,000 | 0.00% | Apr 8, 2026 |
| John Paul Tivnan | Director | – | – | Apr 3, 2026 |
| Andrew Omidvar | Director | – | – | Apr 3, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.8
At 0M shares a day
Change since last report
-33.0%
From 0M shares
Short volume, 20 days
50.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Trinity Biotech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,643 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?